Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX305 in relapsed or refractory lymphoma
CTR20260803Phase 2Active
- Sponsor
- NovoCodex Biopharmaceuticals
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ARX305 in lymphoma, Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), sponsored by NovoCodex Biopharmaceuticals. Started Jun 2026; status: active.
02
Drugs
ARX305
03
Conditions
lymphomaHodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on CTR20260803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260803.